Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position
Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, U.S. Patent No. 9,575,065. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including this newly issued patent. Originally discovered and developed …
Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position Read More »